Doris Augustin

Doris Augustin

Auto-generated profile, based on publicly available information

Doris Augustin

Breast Center Ostbayern, Deggendorf, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MGMonika Graeser
Monika Graeser
OGOleg Gluz
Oleg Gluz
CBClaudia Biehl
Claudia Biehl
DUDaniel Ulbrich-Gebauer
Daniel Ulbrich-Gebauer
MCMatthias Christgen
Matthias Christgen
NHNadia Harbeck
Nadia Harbeck
Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients with cT1-cT4c, cN0–3 HER2+/HR− early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n = 42). Gene expression signatures were analyzed in baseline biopsies using NanoString Breast Cancer 360 panel (n = 117); baseline and on-treatment (week 3) sTIL levels were available in 119 and 76 patients, respectively. Impacts of standardized gene expression signatures on pCR and invasive disease-free survival (iDFS) were estimated by logistic and Cox regression. Results: In all patients, ERBB2 [OR, 1.70; 95% confidence interval (CI), 1.08–2.67] and estrogen receptor (ER) signaling (OR, 1.72; 95% CI, 1.13–2.61) were favorable, whereas PTEN (OR, 0.57; 95% CI, 0.38–0.87) was unfavorable for pCR. After 60 months median follow-up, 13 invasive events occurred (P+T: n = 11, P+T+paclitaxel: n = 2), none following pCR. Gene signatures related to immune response (IR) and ER signaling were favorable for iDFS, all with similar HR about 0.43–0.55. These patterns were even more prominent in the neoadjuvant chemotherapy-free group, where additionally BRCAness signature was unfavorable (HR, 2.00; 95% CI, 1.04–3.84). IR signatures were strongly intercorrelated. sTILs (baseline/week 3/change) were not associated with pCR or iDFS, though baseline sTILs correlated positively with IR signatures. Conclusions: Distinct gene signatures were associated with pCR versus iDFS in HER2+/HR− EBC. The potential role of IR in preventing recurrence suggests that patients with upregulated IR signatures could be candidates for de-escalation concepts in HER2+ EBC.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
UNU. Nitz
U. Nitz
JHJens Bodo Huober
Jens Bodo Huober
BLB. Lisboa
B. Lisboa
NHNadia Harbeck
Nadia Harbeck
HFH. Fischer
H. Fischer
W/West German Study Group /AGO-Mamma
West German Study Group /AGO-Mamma
515 Background: Taxanes and anthracyclines are the most active drugs in breast cancer. Taxane-based adjuvant chemotherapy is considered as standard in node-positive breast cancer, though a large body of evidence derives from trials testing taxanes versus a weak standard (4xAC). Subgroup analyses from several trials indicate that patients with 1 to 3 positive nodes, though at intermediate risk, will have a maximum benefit from taxane-based therapy. Methods: 2,011 patients with primary breast cancer and 1 to 3 positive lymph nodes were randomized from 3/2000 to 8/2005 to a phase III trial comparing 4 cycles E90C600 q3w followed by 4 cycles of docetaxel100 q3w (n=1,008) (Arm A) versus a control Arm B: 6 cycles of E100F500 C500 q3w (n=828) or C600M40F600 d 1 and 8 q4w (n=175). The primary endpoint was the event-free survival (EFS). Secondary endpoints were overall survival, toxicity and quality of life. EC-Doc trial has a 80% power to detect 5 % difference in 5-year EFS. Survival rates will be compared by one-sided log-rank and Cox proportional hazard test. Results: Baseline characteristics were well balanced between both study arms. Median age of patients was 51 years in both arms. Median tumor size 2.0 and 2.05 cm (arm A/B), 69% and 71% of tumors were ER positive (A/B). Toxicity data have been presented earlier (St. Gallen 2005). 312 severe adverse events have been reported (198 in EC/Doc and 114 in CEF/CMF patients). There were 3 therapy-related deaths (2 in arm A and 1 in arm B). At the median follow-up of three years blind analysis of first primary events (34 vs. 64) and deaths (17 vs. 36) was made, so that the independent data safety committee decided to present interim analysis of the trial. Conclusions: Our preliminary data strongly suggest a superiority of one study arm in terms of EFS and early OS in an intermediate risk group. We will present a completely updated survival analysis for the comparison of EC-Doc versus FEC/CMF. No significant financial relationships to disclose.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VMVolkmar Mueller
Volkmar Mueller
SLSibylle Loibl
Sibylle Loibl
ELElena Laakmann
Elena Laakmann
DADoris Augustin
Doris Augustin
FFFelix Flock
Felix Flock
IWIsabell Witzel
Isabell Witzel
2070Background: In order to improve knowledge about treatment and outcome of breast cancer patients with brain metastases (BM) we initiated the registry Brain Metastases in Breast Cancer Network Germany (BMBC, GBG79). Methods: Patients diagnosed with BM since 2000 were included retrospectively and prospectively. 1105 patients from 54 centers were analyzed. Results: Median age at diagnosis of BM was 51 years (20 – 87 years). 49.0 % of patients (472/1105) had HER2-pos., 20.5% (198/1005) triple-neg. and 30.5% (294/1005) luminal primary tumors. One year survival rate from diagnosis of BM was 35.7 % (CI95%: 32.6 – 38.8). Median time from first diagnosis of BM to death in the entire cohort was 7.1 month (CI95%: 5.8 – 7.9). HER2-positive patients had the longest median survival with 12.1 mo. (CI95%: 10.2 – 13.7) compared to 5.5 mo. (CI95%: 4.1 – 7.1) for luminal primary tumors and 4.1 mo. (CI95%: 3.1 – 4.8) for triple-negative patients (p < 0.001). Median OS of patients with BM diagnosed between 2000 and 2006 wa...

25 November 2025
Verified
Other
Open access
MGMonika Graeser
Monika Graeser
OGOleg Gluz
Oleg Gluz
CBClaudia Biehl
Claudia Biehl
DUDaniel Ulbrich-Gebauer
Daniel Ulbrich-Gebauer
MCMatthias Christgen
Matthias Christgen
NHNadia Harbeck
Nadia Harbeck
Supplementary Table 2 shows a comparison of patient characteristics between subjects with and without BC360 and all patients in the trial

1 April 2023
Verified
Other
Open access
MGMonika Graeser
Monika Graeser
OGOleg Gluz
Oleg Gluz
CBClaudia Biehl
Claudia Biehl
DUDaniel Ulbrich-Gebauer
Daniel Ulbrich-Gebauer
MCMatthias Christgen
Matthias Christgen
NHNadia Harbeck
Nadia Harbeck
Supplementary Table 1 lists genes comprising the RNA expression signatures measured with the BC360 panel